Protara Therapeutics has announced encouraging interim results from its ongoing phase 2 STARBORN-1 trial evaluating TARA-002 ...
The European Commission has approved Libtayo (cemiplimab) as the first and only immunotherapy for adult patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback